I haven’t fully explored Marco’s background, so i’m not sure how...

I haven’t fully explored Marco’s background, so i’m not sure how much he knows about funding clinical programs or running a publicly listed company. As far as I can see, Marco’s experience is almost exclusively centred around generics, not new or repurposed treatments. He has experience interacting with the FDA through the ANDA pathway, not the NDA pathway. His commercial expertise is around the sale, marketing and licensing of generic drug brands, which can involve different hurdles to new or repurposed treatments.

So this brings me back to why PAR has recruited him when we are 4 years away from full approval. It just doesn’t make sense to me, unless the approval timelines have changed. Fast track designation brings into play accelerated approval in the United States and PAR may also be able to apply for approval in Australia and Canada prior to the completion of PARA 003. Technically, PAR will have enough results by March next year to start putting an initial application together or to at least start sitting down with regulatory agencies.

I just can’t see Mr Marco accepting the role if it meant he would be sitting around twiddling his thumbs for 2 or 3 years, especially since Oakrum Pharma now have 4 FDA approved ANDA applications and are awaiting the outcome for 7 others. Of course, I am most likely wrong, but we’ll see what Marco has to say once he’s appointed.


If i'm right, then PAR is potentially 4 weeks away from one of the largest short squeezes to ever exist on the ASX.

@Nickporthcawl There are a couple of assumptions I’ve made when making this statement. First, I’m assuming that our new CEO will release a statement when he is appointed on July 1st which will include his vision for the company and an update on the strategic objectives he is expected to achieve. For example, mention of possibly applying for accelerated approval next year and commercialisation strategy. Second, I’m assuming retail will pile into PAR on the chance that PAR could start generating substantial revenues in the next 12-24 months. Third, the low volumes will drive the SP upwards and short sellers will need to cover to the tune of up to 10 million shares, which on current volumes, short sellers can in no way cover in what is a very tightly held stock. Shorts need a capital raise or they’re dust. Fourth, saying it could be one of the largest short squeezes ever may have been a bit of an overstatement. A lot of people will probably sell out in the high $1 or low $2 range.

Not advice, pure speculation, most likely wrong, dyor